In three large-scale, randomized, open-label trials in women with HER2+ breast cancer, treatment with adjuvant trastuzumab resulted in a 52% increase in disease-free survival [7,8] and a 33% reduction in risk of death [8] relative to chemotherapy alone. This evidence concerns the gene ERBB2 and breast carcinoma.